June 12 – 17, 2022
Causing annual epidemics and occasional pandemics, influenza A virus (IAV) is a human pathogen that has severe impact on health and society. Defective interfering particles (DIPs) have been discussed as a potential antiviral therapeutic . Most IAV DIPs are naturally occurring viral mutants harboring large internal deletions in at least one of their eight viral RNA (vRNA) segments. Due to these deletions, DIPs can only replicate in the presence of infectious standard virus (STV), compensating for the missing gene function. In a co-infection, the defective vRNA segment interferes with STV genome replication, which is causative for the therapeutic potential of the DIP. In the presented study, we report on the cell culture-based production and the evaluation of the antiviral potency of a DIP with a deletion in segment 1 vRNA, called DI244.
Please click Download on the upper right corner to see the full abstract.
Marc D. Hein, Anshika Chawla, Prerna Arora, Maurizio Cattaneo, Michael Winkler, Stefan Pöhlmann, Klaus Schughart, Yvonne Genzel, Sascha Y. Kupke, and Udo Reichl, "Production of influenza A virus defective interfering particles in a high cell density perfusion cultivation with continuous virus harvesting" in "Vaccine Technology VIII", Tarit Mukhopadhyay, Merck Research Laboratories, USA; Charles Lutsch, Sanofi Pasteur, France; Linda Hwee-Lin Lua, University of Queensland, Australia; Francesc Godia, Universitat Autònoma de Barcelona, Spain Eds, ECI Symposium Series, (2022). https://dc.engconfintl.org/vaccine_viii/18